Oncology Drugs - Is There a Resistance Development Mechanism?

In addition to using small molecules, especially for things targeting the lizozomopath you could also design biologics, right? Yes. Yet we have made lietack molecules out of monocolonal antibodies,. Rightin we have taken anti bodies that bind the target of interest and chemically modified them with li gaons for a lisaome trafficking receptor. Ah, so there's some leeway on we your lita is a biologic or a small molecule, or a hybrid of the two. And when we're targeting degradation directly, without invoking the endizome licesom pathway, what we're doing is attaching enzymes that can degrade the target to a binding molecule.